Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: GlobeNewswire
BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into therapies for central nervous system (CNS) disorders driven by neuronal excitation-inhibition imbalance, today announced they will present the latest preclinical and clinical data and progress on trials across its precision epilepsy pipeline at the American Epilepsy Society Annual (AES) Meeting, December 5-9, 2025, in Atlanta, Georgia. “The AES meeting is a cornerstone for the epilepsy community, bringing together science, clinical innovation, and patient advocacy,” said Steven Petrou, chief scientific officer and co-founder of Praxis. “We’re excited to continue showcasing the strength of our precision epilepsy pipeline and the potential to meaningfully impact the lives of people living with epilepsy. Our presentations at AES reflect the continued translation of our science into clinical progress and reinforce our co
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- How EMBOLD Efficacy Stop And Ulixacaltamide FDA Pathway At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 [Seeking Alpha]Seeking Alpha
- Top Midday Gainers [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines (NASDAQ:PRAX) was given a new $304.00 price target on by analysts at Needham & Company LLC.MarketBeat
- Praxis Precision Medicines (NASDAQ:PRAX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
PRAX
Earnings
- 11/5/25 - Beat
PRAX
Sec Filings
- 11/21/25 - Form 4
- 11/21/25 - Form 4
- 11/21/25 - Form 4
- PRAX's page on the SEC website